Skip to content
TrialScanner

NCT07123350

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

No phase registeredActive, not recruitingTAKCollaborator

Registry record

Lead sponsor
Vanderbilt University Medical Center
Conditions
Inflammatory Bowel Disease (IBD); Crohn&Amp;#39;s Disease (CD); Ulcerative Colitis (UC)
Primary completion
Mar 31, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT07123350 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07123350: Evaluating the Shift From... | TrialScanner